# An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

> **NCT07282262** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Ivosidenib
- **DRUG:** Lenvatinib
- **BIOLOGICAL:** PD-1/PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT07282262
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282262, "An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07282262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*